Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform

Financing round led by Nextech Invest Proceeds to advance lead oncology programs into the clinic and broaden early-stage pipeline NEW HAVEN, Conn., April 4, 2018 -- (Healthcare Sales & Marketing Network) -- Arvinas LLC, a private biotechnology compa... Biopharmaceuticals, Venture Capital, Personnel Arvinas, Proteolysis Targeting Chimeras
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news